Nov 4, 8:00 AM ET
Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $268.9 million, up 12% from $239.5 million a year earlier, and reiterated full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion. Net income fell to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87, a year earlier, mainly due to higher milestone charges and new royalty charges tied to the Novitium license.
- Q3 2026 WAKIX net revenue of $268.9 million, up 12% from $239.5 million in Q3 2025
- Net income of $48.2 million, or $0.81 per diluted share, versus $50.9 million, or $0.87, in Q3 2025
- Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion reiterated
- Peter Anastasiou will succeed Jeffrey Dayno, MD, as President and CEO effective January 1, 2027
Read the filing on SEC.gov ↗
Oct 13, 8:00 AM ET
Harmony Biosciences said CEO Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026, as part of a planned succession. Chief Operating Officer Peter Anastasiou will become President, Chief Executive Officer and a Class I director on January 1, 2027, and the company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
- Dayno retires as President and CEO and steps down from the board on December 31, 2026, and will serve as a non-executive advisor through 2027.
- Anastasiou, COO since April 2026, becomes President and CEO effective January 1, 2027, and joins the board as a Class I director.
- The company reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.
- Harmony still expects to report multiple ascending dose study data for BP-205 in Q4 2026.
Read the filing on SEC.gov ↗
Aug 4, 8:05 AM ET
Harmony Biosciences reported second-quarter 2026 net product revenue for WAKIX of $261.3 million, up 30% from $200.5 million a year earlier, and net income of $75.4 million, or $1.28 per diluted share, versus $39.8 million, or $0.68, in the prior-year quarter. The company reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and shared initial Phase 1 single ascending dose data for its orexin-2 agonist BP-205.
- Net product revenue of $261.3 million, up 30% year over year; estimated average patients rose by 450 to 8,950.
- Net income of $75.4 million, or $1.28 per diluted share, compared with $39.8 million, or $0.68, a year earlier.
- Cost of product sold rose to 24.2% of net product revenue from 19.0%, mainly due to new royalties related to the Novitium license agreement.
- Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion was reiterated, not changed; cash and investments were $962.5 million as of June 30, 2026.
Read the filing on SEC.gov ↗
Jul 16, 8:35 AM ET
Harmony Biosciences said preliminary, unaudited second-quarter 2026 net product revenue for WAKIX was about $261 million, a company record and 30% higher than a year earlier, and reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. The company also said CFO Glenn Reicin stepped down effective July 16, 2026, with Controller Stephen Mollichella named interim principal financial officer while a permanent CFO is sought.
- Preliminary Q2 2026 WAKIX net product revenue of about $261 million, up 30% year over year and 21% over Q1 2026
- 2026 net product revenue guidance of $1.0 billion to $1.04 billion reaffirmed
- Glenn Reicin stepped down as CFO effective July 16, 2026; he is receiving severance and a pro-rated target bonus under a separation agreement
- Full Q2 2026 financial results and business update scheduled for August 4, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.